Inhibitors of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel have potential applications in the therapy of secretory diarrheas and polycystic kidney disease. In a recent study, several highly polar ␣-aminoazaheterocyclic-methylglyoxal adducts were reported to reversibly inhibit CFTR chloride channel activity with IC 50 values in the low picomolar range (J Pharmacol Exp Ther 322:1023-1035, 2007), more than 10,000-fold better than that of thiazolidinone and glycine hydrazide CFTR inhibitors previously identified by highthroughput screening. In this study, we resynthesized and evaluated the ␣-aminoazaheterocyclic-methylglyoxal adducts reported to have high CFTR inhibition potency (compounds 5, 7, and 8). We verified that the reported synthesis procedures produced the target compounds in high yield. However, we found that these compounds did not inhibit CFTR chloride channel function in multiple cell lines at up to 100 M concentration, using three independent assays of CFTR function including short-circuit current analysis, whole-cell patch-clamp experiments, and yellow fluorescence protein-fluorescence quenching. As positive controls, approximately 100% of CFTR inhibition was found by thiazolidinone and glycine hydrazide CFTR inhibitors. Our data provide direct evidence against CFTR inhibition by ␣-aminoazaheterocyclic-methylglyoxal adducts.
The cystic fibrosis transmembrane conductance regulator (CFTR) protein is a cAMP-regulated chloride channel, which when mutated causes the hereditary disease cystic fibrosis (Sheppard and Welsh, 1999) . CFTR in intestinal epithelial cells provides the primary route for chloride secretion in enterotoxin-mediated secretory diarrheas such as cholera and traveler's diarrhea (Thiagarajah and Verkman, 2005) . CFTR has also been implicated in the progressive expansion of renal cysts in polycystic kidney disease (Li et al., 2004; Yang et al., 2008) . Thus, CFTR is a well validated target for drug discovery . CFTR activators have potential use in the therapy of cystic fibrosis, dry eye syndrome, and constipation. CFTR inhibitors have potential use in the therapy of secretory diarrheas and polycystic kidney disease. Our laboratory previously developed fluorescence, cell-based assays to identify CFTR activators (Galietta et al., 2001; Ma et al., 2002a) and inhibitors (Ma et al., 2002b; Muanprasat et al., 2004) , and we used secondary electrophysiological and biochemical assays to verify their target and mechanism. Screening of ϳ200,000 synthetic small molecules yielded thiazolidinone and glycine hydrazide CFTR inhibitors with potencies down to ϳ0.2 M (Ma et al., 2002b; Muanprasat et al., 2004) . The glycine hydrazides block the CFTR pore at its external surface, which allowed the synthesis of nonabsorbable polyethylene glycol and lectin adducts that do not cross membranes and block intestinal fluid secre-tion in animals models of cholera (Sonawane et al., 2006 (Sonawane et al., , 2007 . Routaboul et al. (2007) recently reported that ␣-aminoazaheterocyclic-methylglyoxal adducts inhibit CFTR chloride channel function completely and reversibly, with low picomolar IC 50 values, more than 10,000-fold better than the most potent known CFTR inhibitors. The picomolar-potency compounds were identified by screening a collection of seven ␣-aminoazaheterocyclic-methylglyoxal adducts. These adducts had been reported previously in a study that described an efficient, one-step synthesis approach involving the reaction of methylglyoxal with ␣-aminoazaheterocycles (Routaboul et al., 2002) . The exceptionally high potency and reversibility of the ␣-aminoazaheterocyclic-methylglyoxals was surprising for several reasons. First, prior screening of 200,000 compounds for CFTR inhibition produced only one compound with an IC 50 less than 1 M, with an overall low verified hit rate of ϳ1/50,000 (Ma et al., 2002b; Muanprasat et al., 2004) . Discovery of picomolar-potency CFTR inhibitors by screening seven compounds of a single chemical class is surprising, particularly because the compounds were tested for CFTR inhibition without a rational basis. Second, most channel inhibitors with picomolar potency are animal toxins rather than small, synthetic molecules (Favreau et al., 2001; Grunnet et al., 2001; Benton et al., 2003; Castle et al., 2003) . Last, contrary to the data of Routaboul et al. (2007) , very slow (more than hours) reversibility of picomolar-affinity inhibitors is expected even in the diffusion limit (Bkaily et al., 1985) .
For these reasons, and because of the potential major therapeutic implications of picomolar-potency CFTR inhibitors, we reevaluated the findings of Routaboul et al. (2007) . We verified the high-yield synthesis of ␣-aminoazaheterocyclicmethylglyoxal adducts, as originally reported by Routaboul et al. (2002) ; however, using multiple assays, cell lines, and concentrations, and with appropriate positive controls, we were unable to demonstrate CFTR inhibition by the ␣-aminoazaheterocyclic-methylglyoxals.
Materials and Methods

Synthesis Procedures.
1 H NMR spectra were obtained in D 2 O, pH 7, using a 400 MHz Varian spectrometer. Mass spectrometry was done on a Waters LC/MS System (Alliance HT 2790ϩZQ, HPLC; model 2690; Waters, Milford, MA). Flash chromatography was performed using EM silica gel (230 -400 mesh), and thin-layer chromatography (TLC) was done on Merck Silica Gel 60 F254 plates.
Synthesis of ␣-Aminoazaheterocycle-Methylglyoxal Adducts. Compounds 2, 3, 4, 5, 6, and 8 were synthesized in high yield by using the methods of Routaboul et al. (2002 Routaboul et al. ( , 2007 .
On average, a mixture of the aminoazaheterocycle and a dilute solution of methylglyoxal were stirred under argon at ϳ50°C for 1 to 2 days (until reaction was completed by LC/MS). The residue after evaporation was purified by a combination of precipitation, recrystallization, normal/reverse-phase column chromatography, and preparative TLC (Routaboul et al., 2002 (Routaboul et al., , 2007 (Ma et al., 2002a) , were plated in black-walled, 96-well plates with transparent plastic bottoms (Costar; Corning Life Sciences, Acton, MA), cultured overnight to confluence, washed three times with phosphate-buffered saline (PBS), and incubated with test compounds in a final volume of 60 l. YFP-H148Q fluorescence was measured using a fluorescence plate reader (FLUOstar Optima; BMG Labtech, Offenburg, Germany) equipped with custom excitation and emission filters (500 and 544 nm, respectively; Chroma Technology Corp., Brattleboro, VT). Fluorescence intensity in each well was measured for a total of 14 s. In each well, 100 l of PBS/I Ϫ (PBS with 100 mM Cl Ϫ replaced by I Ϫ ) was injected by a syringe pump at 2 s after the start of data collection. The initial rate of fluorescence decay caused by I Ϫ influx was measured to determine CFTR activity (Ma et al., 2002a) .
Short-Circuit Current Measurements. FRT cells (stably expressing human WT CFTR) were cultured on Snapwell filters with 1-cm 2 surface area (Costar; Corning Life Sciences) to resistance Ͼ1000 ⍀⅐cm 2 , as described previously (Ma et al., 2002a) . Filters were mounted in an EasyMount Chamber System (Physiologic Instruments, San Diego, CA). For apical Cl Ϫ current measurements, the basolateral hemichamber contained the following: 130 mM NaCl, 2.7 mM KCl, 1.5 mM KH 2 PO 4 , 1 mM CaCl 2 , 0.5 mM MgCl 2 , 10 mM Na-HEPES, and 10 mM glucose, pH 7.3. The basolateral membrane was permeabilized with amphotericin B (250 g/ml) for 30 min. In the apical solution, 65 mM NaCl was replaced by sodium gluconate, and CaCl 2 was increased to 2 mM. Solutions were bubbled with 95% O 2 /5% CO 2 and maintained at 37°C. Current was recorded using a DVC-1000 voltage clamp (World Precision Instruments, Inc., Sarasota, FL) using Ag/AgCl electrodes and 1 M KCl agar bridges. Some measurements were done using T84 colonic epithelial cells and primary cultures of human bronchial epithelial cells, which natively express human WT CFTR), as described previously (Galietta et al., 2000) . Short-circuit current was also measured in freshly isolated mouse ileum using symmetric bicarbonate-containing solutions, as described previously (Thiagarajah et al., 2004) .
Whole-Cell Patch Clamp. Patch-clamp experiments were performed at room temperature on FRT cells stably expressing human WT CFTR, as described previously . Some experiments were done using Chinese hamster ovary (CHO) cells after transient transfection with human WT CFTR. In brief, the pipette solution contained the following: 120 mM CsCl, 10 mM TEA-Cl, 0.5 mM EGTA, 1 mM MgCl 2 , 40 mM mannitol, 10 mM Cs-HEPES, pH 7.3, 1 mM MgATP, and 0.4 g/ml catalytic subunit of protein kinase A. The bath solution contained the following: 150 mM NaCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM glucose, 10 mM mannitol, and 10 mM 
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Na-HEPES, pH 7.4. The cell membrane was clamped at specified voltages using an EPC-7 patch-clamp amplifier (List Medical Instruments, Darmstadt, Germany). Voltage stimulation consisted of alternate pulses of Ϫ100 and ϩ100 mV from a holding potential of 0 mV. Where needed, a full range of voltage pulses was applied in 20-mV steps, with pulse duration of 800 ms. Data were filtered at 500 Hz and digitized at 1000 Hz using an Instrutech ITC-16 AD/DA interface and the PULSE (HEKA, Lambrecht, Germany) software. Inhibitors were applied by extracellular perfusion.
Transient Transfection of CHO Cells. CHO cells, plated in 6-well plates (500,000 cells/well), were transfected with 4 g of plasmid DNA and 10 l of Lipofectamine 2000 (Invitrogen, Carlsbad, CA) per well according to the manufacturer's instructions. Cells were cotransfected with two plasmids carrying the coding sequence for CFTR and the yellow fluorescent protein in a 3:1 M ratio. After 24 h, cells were detached by trypsinization and sorted with a fluorescenceactivated cell sorter. Fluorescent cells were isolated and plated in 35-mm Petri dishes for whole-cell patch-clamp recordings.
Results
Synthesis and Characterization of ␣-Aminoazaheterocyclic-Methylglyoxal Adducts. Figure 1A shows the chemical structures of the two CFTR inhibitors, CFTR inh -172 and MalH-1, identified previously by high-throughput screening. Figure 1B shows the ␣-aminoazaheterocyclic-methylglyoxal adducts reported by Routaboul et al. (2007) to strongly inhibit CFTR with IC 50 values in the low picomolar to nanomolar range. All adducts were a mixture of at least two diastereomers, in approximately 50:50 proportion, and were highly soluble in water, except for 8ab, which had low solubility. By preparative TLC and column chromatography, we were successful in separating diastereomers 3ab but not 5ab. Routaboul et al. (2007) tested all adducts as diastereomeric mixtures, with the exception of the adduct 5a. Because we found that mixture 5ab was inactive at concentrations to 10 6 -fold greater than the reported IC 50 by Routaboul et al. (2007) , we did not work further in separating 5a and 5b. Figure 1C shows the chemical reaction scheme reported by Routaboul et al. (2002) for efficient, one-step synthesis of ␣-aminoazaheterocyclic-methylglyoxals. The reported reaction conditions and work-up procedures gave the target adducts with yields Ͼ50%. The reactions were monitored by TLC and LC/MS, and completion of reaction was indicated by absence of the ␣-aminoazaheterocycle. In most cases, the purified material showed two clear peaks with corresponding molecular weights of adducts, indicating presence of diastereomers (see supplemental data). NMR spectra of all adducts showed the presence of two peaks corresponding to methyl protons and two peaks corresponding to ring C-H protons. Our 1 H NMR spectra of 3ab and 8ab were in agreement with previously reported spectra in Routaboul et al. (2007) . In this study, we also present the NMR data for 2ab, 4ab, 5ab, and 6ab (see supplemental data), which were not included in the Routaboul et al. (2002) report.
CFTR Inhibition Measurements. Measurements of CFTR inhibition were done first using FRT cells expressing human wild-type CFTR, an established cell line that was used for primary high-throughput screening to identify inhibitors and activators of wild-type CFTR (Ma et al., 2002a,b; Muanprasat et al., 2004) , and for secondary electrophysiological assays . This cell line expresses CFTR strongly and contains no other cAMP-regulated anion current. Figure 2A shows representative short-circuit current measurements, in which apical membrane current provides a direct measure of CFTR chloride conductance. Apical membrane current rapidly increased after addition of the cell-permeable cAMP agonist forskolin. However, compounds 3ab, 4ab, 5ab, and 8ab did not demonstrably reduce apical membrane current, which was rapidly reduced to approximately zero after addition of the CFTR inhibitor MalH-1 at the end of each measurement. A similar lack of CFTR inhibition was found for compounds 2ab and 6ab (data not shown). In control experiments, apical membrane current was reduced in a concentration-dependent manner by the CFTR inhibitors, CFTR inh -172 (Fig. 2B) and MalH-1 (data not shown), with approximately 100% inhibition seen at higher concentrations (Ma et al., 2002b; Sonawane et al., 2006) .
We also tested all compounds in a fluorescence-based jpet.aspetjournals.org plate-reader assay in which CFTR function is assayed from the rate of iodide influx (negative slope) in FRT cells coexpressing human WT CFTR and the cytoplasmic iodide sensor YFP-H148Q (Ma et al., 2002b) . In this assay, CFTR inhibition reduces iodide influx and thus decreases the rate of quenching of green fluorescent protein fluorescence (negative slope). Figure 2C shows concentration-inhibition data for the known CFTR inhibitor MalH-4,4Ј-diisothiocyanatostilbene-2,2Ј-disulfonic acid (Sonawane et al., 2007) , along with the 5ab and 8ab ␣-aminoazaheterocyclic-methylglyoxals, neither of which measurably inhibited CFTR at any concentration tested. A similar lack of CFTR inhibition was found for compounds 3ab and 4ab (data not shown). Short-circuit current measurements were also done on two cell types that natively express human wild-type CFTR, T84 colonic epithelial cells and primary cultures of human bronchial epithelial cells, as well as in mouse intestine. Figure 3 shows short-circuit current data for active chloride secretion, in which measurements were done in nonpermeabilized cells in the absence of a chloride gradient. As described above, the increased current corresponds to apical membrane CFTR chloride conductance. Forskolin produced a prompt increase in chloride current as a result of CFTR activation in T84 cells. Each of the ␣-aminoazaheterocyclic-methylglyoxals tested did not reduce chloride current (Fig. 3A) . In each case, the CFTR inhibitor CFTR inh -172 reduced current to near zero at the end of the experiment. A similar lack of inhibition was found in human bronchial epithelial cells for compound 8ab (Fig. 3B) . In addition, the ␣-aminoazaheterocyclicmethylglyoxals at high concentrations did not inhibit shortcircuit current in mouse ileal epithelium (Fig. 3C) .
Whole-cell patch-clamp recordings in FRT cells were obtained as another independent, direct measure of CFTR chloride channel function. Representative data for compound 5ab is provided. Figure 4A shows the whole-cell membrane current in response to voltage pulses at Ϫ100 mV (filled symbols) and ϩ100 mV (open symbols) from a holding potential of 0 mV. Where indicated by letters (Fig. 4, a-f) , the alternate voltage stimulation was interrupted to apply voltage pulses in the range Ϫ100 to ϩ100 mV in 20-mV steps. The resulting current-voltage relationships and membrane currents are shown in Fig. 4 , B and C, respectively. Membrane currents were very small at baseline, but they increased strongly upon stimulation with CPT-cAMP (100 M). The voltage relationship of cAMP-activated currents was linear (Fig. 4B) , as expected for CFTR-dependent activity. Subsequent addition of compound 5ab (100 M) did not affect membrane currents at all membrane potentials (Fig. 4, A-C) , whereas CFTR inh -172 (10 M) reduced CFTR current to near zero. A similar whole-cell patch-clamp analysis for compounds 5ab and 8ab, jpet.aspetjournals.org in the concentration range of 100 nM to 100 M, showed no significant CFTR inhibition. Looking further for a possible explanation for our conflicting results, we repeated the whole-cell patch-clamp recordings on CFTR-expressing CHO cells, the cell type used by Routaboul et al. (2007) . Figure 4D shows that, similar to FRT cells, no inhibition was found for compound 5ab at high concentrations. Thus, the short-circuit current, fluorescence, and patchclamp analyses provide direct evidence against CFTR inhibition by ␣-aminoazaheterocyclic-methylglyoxal adducts.
Discussion
The goal of our study was to evaluate the CFTR inhibition potency of the ␣-aminoazaheterocyclic-methylglyoxal adducts reported by Routaboul et al. (2007) . This investigation was motivated by the potential usefulness of potent small-molecule CFTR inhibitors in the therapy of secretory diarrheas and polycystic kidney disease. Based on the much greater reported potency of the ␣-aminoazaheterocyclic-methylglyoxals than known CFTR inhibitors, verification of their potency and mechanism of action is important in selecting compound classes for clinical development. Although our experiments reproduced the synthesis procedures and analytical data of several ␣-aminoazaheterocyclic-methylglyoxals, we were unable to demonstrate CFTR inhibition using multiple cell lines and several established assay methods, with experiments done in two independent laboratories in San Francisco, CA, and Genoa, Italy. In each case, positive controls with known CFTR inhibitors validated the sensitivity of the assays. As mentioned in the Introduction, for a number of reasons, it was quite surprising a priori that CFTR inhibitors with low picomolar potency could be discovered after screening of a very small set of compounds of a single chemical class. These compounds had been synthesized previously as examples of a novel, one-step stereoselective reaction of methylglyoxal with ␣-aminoazaheterocycle (Routaboul et al., 2002) .
We cannot account for the CFTR inhibition potency data reported by Routaboul et al. (2007) . The simple, one-step synthesis, done exactly as reported by Routaboul et al. (2002) , yielded the compounds in high yield. Analytical data for the compounds reported by Routaboul et al. (2002) and those synthesized here were in agreement. Mass spectra showed the correct molecular weights, which indicated the adduct formation from two methylglyoxal molecules with one ␣-aminoazaheterocycle.
With regard to the CFTR inhibition studies reported by Routaboul et al. (2007) , there seem to be technical concerns and inconsistencies. Our whole-cell patch-clamp recordings show that the lack of inhibition in short-circuit current and fluorescence experiments could not be due to an unusual voltage dependence of ␣-aminoazaheterocyclic-methylglyoxals. We found no significant inhibition at all of the applied voltages in the Ϫ100 to ϩ100 mV range, the same range used by Routaboul et al. (2007) . We also tested concentrations up to 10 6 -fold higher than the reported IC 50 , making it unlikely that a lack of inhibition was due to insufficient concentration or membrane permeability. Our whole-cell patch-clamp results in FRT and CHO cells do not agree with those of Routaboul et al. (2007) in which 10 pM, a concentration that is 10 times lower than the IC 50 reported by the same authors, fully blocked CFTR currents. The 6-methoxy-N-(3-sulfopropyl)quinolinium fluorescence measurements (see Fig. 7 in Routaboul et al., 2007) appear to be internally inconsistent as well, because inhibition was determined from the initial upslope of the curves in the first few seconds just after nitrate addition in the presence of the inhibitor. Inhibition at this early time is inconsistent with their data in Fig. 4C , showing ϳ1-min kinetics for onset of inhibition. We also note that such a rapid onset of inhibition is inconsistent with the high polarity and solubility of the ␣-aminoazaheterocyclic-methylglyoxals, because their permeation across a cell plasma membrane to bind to an inhibition site in the cell interior should be very slow. An interior binding site is mandated by the data in Fig. 8 of Routaboul et al. (2007) , showing remarkably weaker CFTR inhibition after mutation (G551D) at a residue located in a cytosolic domain of CFTR. Finally, the intestinal short-circuit current measurements in Fig. 10 of Routaboul et al. (2007) appear to be flawed in that inhibitors were added before rather than after forskolin simulation of CFTR. Whereas an appropriate forskolin response was seen in their Fig. 10A , the near-zero baseline current in the intestinal strips studied in Fig. 10 , B and C, before inhibitor addition, suggests nonviable tissue. The reduced forskolin response in these panels is thus a consequence of poor tissue viability rather than CFTR inhibition. We found no inhibition of CFTR-dependent short-circuit current in mouse intestine by the ␣-aminoazaheterocyclic-methylglyoxals.
In conclusion, the ␣-aminoazaheterocyclic-methylglyoxal adducts reported by Routaboul et al. (2007) lack CFTR inhibition activity and are thus not candidates for further development.
